Skip to main content
Figure 3 | Lipids in Health and Disease

Figure 3

From: Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes

Figure 3

Safety evaluation during follow-up after treatment. Liver dysfunction and MRSE marker were from lowest levels within 3 days after admission and at 30th day. (A, B, C) liver dysfunction marker ALT, TBIL and MRSE marker CK at 0th and 30th after treatment. Side effects was not observed in combination group and statins group after treatment. Data presented as mean ± SE.

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X